Amylin Pharmaceuticals, Inc. Company Profile

Amylin Pharmaceuticals, Inc.

9373 Towne Centre Drive
San Diego, CA 92121-3027
United States
Tel: 1/858/552-2200
URL: http://www.amylin.com
Primary Symbol & Exchange:
AMLN - Common Stock - NASDAQ
Industry:
Pharmaceutical
+  SIC Industry Code:
+  NAICS Industry Code:
Mergers & Acquisitions:
Amylin Pharmaceuticals, Inc. Mergers and Acquisitions
Thomson Financial Business Description:
The Group's principal activity is to discover, develop and commercialize potential drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The Group has two approved products, BYETTA(R) (exenatide) injection, and SYMLIN(R) (pramlintide acetate) injection, both of which were commercially launched in the United States in 2005. BYETTA is the first and only approved medicine in a new class of compounds called incretin mimetics. SYMLIN is the first and only approved medicine in a new class of compounds called amylinomimetics. The Group has a global development and commercialization agreement for exenatide, including BYETTA and any sustained-release formulations of BYETTA, including exenatide LAR, with Eli Lilly & Company.
Research Alerts: Amylin Pharmaceuticals, Inc. RSS Feed Subscribe with My Yahoo!
Receive alerts on the latest reports on Amylin Pharmaceuticals, Inc.

Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.

Premium Content Results:







Search for more premium content on Amylin Pharmaceuticals, Inc.